Skip to main
IRD
IRD logo

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc is advancing its pipeline of therapies for inherited retinal diseases and other ocular conditions, which includes promising adeno-associated virus-based gene therapies and Phentolamine, a treatment for presbyopia and keratorefractive surgery outcomes. Recent positive topline results from the Phase 3 VEGA-3 trial for phentolamine demonstrated significant improvements in visual acuity, with 17.3% of patients experiencing substantial gains compared to 9.2% for the placebo group. Furthermore, the anticipated sNDA submission for presbyopia in the second half of 2025 reflects Opus Genetics' commitment to innovation and potential market expansion, indicating a robust growth trajectory for the company.

Bears say

Opus Genetics faces significant risks that could negatively impact its financial outlook, particularly the potential failure of its product candidates to meet peak commercial revenue estimates due to limitations in market size, penetration rates, and pricing strategies. Additionally, the company may struggle to secure necessary capital resources for ongoing operations, which could impede program development and commercialization efforts. These factors contribute to a decreased confidence in Opus Genetics's ability to sustain growth and profitability in the competitive ophthalmic biopharmaceutical space.

Opus Genetics (IRD) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.